PI Global Investments
Hedge Funds

Global Cord Blood Co. (NYSE:CO) Short Interest Update

Global Cord Blood logo

Global Cord Blood Co. (NYSE:COGet Rating) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 252,900 shares, a growth of 62.1% from the June 15th total of 156,000 shares. Based on an average daily volume of 196,000 shares, the short-interest ratio is currently 1.3 days. Approximately 0.7% of the company’s stock are short sold.

Hedge Funds Weigh In On Global Cord Blood

Hedge funds and other institutional investors have recently made changes to their positions in the business. Natixis Advisors L.P. grew its position in Global Cord Blood by 1.7% in the 4th quarter. Natixis Advisors L.P. now owns 177,621 shares of the medical research company’s stock valued at $744,000 after buying an additional 3,052 shares in the last quarter. National Asset Management Inc. bought a new position in shares of Global Cord Blood in the first quarter valued at approximately $39,000. Campbell & CO Investment Adviser LLC bought a new position in shares of Global Cord Blood in the first quarter valued at approximately $56,000. DGS Capital Management LLC acquired a new position in shares of Global Cord Blood during the fourth quarter valued at approximately $144,000. Finally, Rockefeller Capital Management L.P. bought a new stake in Global Cord Blood during the fourth quarter worth approximately $331,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Global Cord Blood Stock Up 0.4 %

Ad Legacy Managed CPA

FORGET 99% of The Stock Market

Whether you have $100 or $100M, this is a trading secret anyone could use right now.

NYSE CO traded up $0.01 during trading hours on Friday, hitting $2.53. The company had a trading volume of 16,934 shares, compared to its average volume of 92,747. Global Cord Blood has a fifty-two week low of $2.10 and a fifty-two week high of $5.50. The firm has a market cap of $307.52 million, a P/E ratio of 3.95 and a beta of 0.26. The business has a fifty day simple moving average of $2.83 and a 200-day simple moving average of $3.57.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Global Cord Blood in a research note on Friday, June 3rd. They issued a “strong-buy” rating on the stock.

About Global Cord Blood

(Get Rating)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People’s Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Global Cord Blood right now?

Before you consider Global Cord Blood, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Global Cord Blood wasn’t on the list.

While Global Cord Blood currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Source link

Related posts

Tougher times for private equity

Miles

Is Xylem (XYL) A High Growth Investment?

Miles

UPDATE 2-U.S. hedge fund Engine Capital urges Univar to consider sale, other options

Miles

Leave a Comment

SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.

    100% secure your website.